Heat shock protein inhibitors and vaccines as new agents in cancer treatment.

Physiological regulation of Akt activity and stability. Am J Transl Res (2010) 1.95

Forkhead box M1 is regulated by heat shock factor 1 and promotes glioma cells survival under heat shock stress. J Biol Chem (2012) 0.93

Custom CGH array profiling of copy number variations (CNVs) on chromosome 6p21.32 (HLA locus) in patients with venous malformations associated with multiple sclerosis. BMC Med Genet (2010) 0.92

The role of heat shock proteins in bladder cancer. Nat Rev Urol (2013) 0.91

Insulin-degrading enzyme (IDE): a novel heat shock-like protein. J Biol Chem (2012) 0.90

Separation and identification of HSP-associated protein complexes from pancreatic cancer cell lines using 2D CN/SDS-PAGE coupled with mass spectrometry. J Biomed Biotechnol (2011) 0.80

Heat shock protein expression in canine osteosarcoma. Cell Stress Chaperones (2011) 0.78

Expression of heat shock proteins in premalignant and malignant urothelial lesions of bovine urinary bladder. Cell Stress Chaperones (2012) 0.78

Gemcitabine-induced pulmonary toxicity during adjuvant therapy in a patient with pancreatic cancer. JOP (2008) 2.39

Cell adhesion molecules: role and clinical significance in cancer. Cancer Invest (2009) 1.80

The role of angiogenesis in solid tumours: an overview. Eur J Intern Med (2009) 1.72

Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol (2005) 1.69

Screening for early pancreatic ductal adenocarcinoma: an urgent call! JOP (2009) 1.57

Disparities in colorectal cancer in African-Americans vs Whites: before and after diagnosis. World J Gastroenterol (2009) 1.55

Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer. J Clin Oncol (2012) 1.52

Erlotinib-induced skin rash in patients with non-small-cell lung cancer: pathogenesis, clinical significance, and management. Clin Lung Cancer (2009) 1.44

Oral osteonecrosis associated with the use of zoledronic acid: first case of a patient with advanced pancreatic cancer and bone metastases. JOP (2009) 1.43

Platinum-based therapy in adenosquamous pancreatic cancer: experience at two institutions. JOP (2014) 1.39

Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer. J Clin Oncol (2010) 1.38

Panitumumab the first fully human monoclonal antibody: from the bench to the clinic. Anticancer Drugs (2007) 1.30

Infusion-related and hypersensitivity reactions of monoclonal antibodies used to treat colorectal cancer--identification, prevention, and management. J Support Oncol (2007) 1.29

Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians. Clin Cancer Res (2006) 1.29

Pancreatic neoplasm in 2011: an update. JOP (2011) 1.28

Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review. Met Based Drugs (2010) 1.18

Skin rash secondary to bevacizumab in a patient with advanced colorectal cancer and relation to response. Anticancer Drugs (2006) 1.17

FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG). Breast Cancer Res Treat (2009) 1.08

Cancers of the appendix: review of the literatures. ISRN Oncol (2011) 1.07

Second line therapy for advanced pancreatic adenocarcinoma: where are we and where are we going? Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010. JOP (2010) 1.06

Long-term survival in a patient with acinar cell carcinoma of pancreas. A case report and review of literature. JOP (2007) 1.06

First-line treatment for advanced pancreatic cancer. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011. JOP (2011) 1.05

Hypersensitivity reactions to oxaliplatin and other antineoplastic agents. Curr Allergy Asthma Rep (2008) 1.05

Aurora kinase inhibitors as anti-cancer therapy. Anticancer Drugs (2010) 1.04

Primary squamous cell carcinoma of the liver. J Gastrointestin Liver Dis (2009) 1.03

Prolonged survival in a patient with BRCA2 associated metastatic pancreatic cancer after exposure to camptothecin: a case report and review of literature. Anticancer Drugs (2009) 1.02

Toxicity and efficacy of 5-fluorouracil and capecitabine in a patient with TYMS gene polymorphism: A challenge or a dilemma? Clin Colorectal Cancer (2009) 1.02

Treatment of locally advanced pancreatic cancer: the role of radiation therapy. Int J Radiat Oncol Biol Phys (2011) 1.02

Advancements in the management of pancreatic cancer: 2013. JOP (2013) 1.02

Developments in the treatment of non-small cell lung cancer. Anticancer Res (2007) 1.01

Controversies in the adjuvant treatment of pancreatic adenocarcinoma. JOP (2007) 1.00

Immunotherapy updates in pancreatic cancer: are we there yet? Ther Adv Med Oncol (2013) 1.00

A randomized phase III study of the docetaxel/carboplatin combination versus docetaxel single-agent as second line treatment for patients with advanced/metastatic non-small cell lung cancer. BMC Cancer (2010) 0.99

Capecitabine and hand-foot syndrome. Expert Opin Drug Saf (2010) 0.99

Gastrointestinal stromal tumors of the pancreas. JOP (2010) 0.98

Role and cost effectiveness of PET/CT in management of patients with cancer. Yale J Biol Med (2010) 0.97

Erlotinib-induced skin rash. Pathogenesis, clinical significance and management in pancreatic cancer patients. JOP (2008) 0.97

Hypersensitivity vasculitis associated with leuprolide (Lupron). Cutan Ocul Toxicol (2010) 0.96

IGF system in cancer: from bench to clinic. Anticancer Drugs (2011) 0.96

Three-drug combination regimen in pancreatic cancer treatment: are we there yet? JOP (2011) 0.96

Oxaliplatin as first-line treatment in inoperable biliary tract carcinoma: a multicenter phase II study. Oncology (2006) 0.95

Supportive and palliative care of pancreatic cancer. JOP (2007) 0.95

Optimal second line treatment options for gemcitabine refractory advanced pancreatic cancer patients. Can we establish standard of care with available data? JOP (2008) 0.94

Methods and rationale for the early detection of pancreatic cancer. Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010. JOP (2010) 0.94

Targeted (and chemotherapeutic) agents as maintenance treatment in patients with metastatic non-small-cell lung cancer: current status and future challenges. Cancer Treat Rev (2012) 0.94

Role of pregabalin in treatment of oxaliplatin-induced sensory neuropathy. Anticancer Res (2010) 0.93

Radiation recall phenomenon secondary to bevacizumab in a patient with pancreatic cancer. JOP (2008) 0.93

Is there an optimal neoadjuvant therapy for locally advanced pancreatic cancer? JOP (2007) 0.93

FOLFIRINOX: from the ACCORD study to 2014. JOP (2014) 0.91

Bisphosphonate use in patients with lung cancer and bone metastases: recommendations of a European expert panel. J Thorac Oncol (2009) 0.90

Pulmonary thromboembolism in AIDS patient with chronic venous insufficiency, pulmonary tuberculosis and breast cancer: a case report and pathophysiology review. Rev Inst Med Trop Sao Paulo (2006) 0.90

Assessing risk and mortality of venous thromboembolism in pancreatic cancer patients. Anticancer Res (2010) 0.89

Mitomycin--C-induced thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: cumulative toxicity of an old drug in a new era. Clin Colorectal Cancer (2011) 0.89

Pulmonary toxicity associated with gemcitabine. JOP (2010) 0.89

Genetic alterations in pancreatic cancer. World J Gastroenterol (2007) 0.89

Triphendiol (NV-196), development of a novel therapy for pancreatic cancer. Anticancer Drugs (2011) 0.89

Epidermal growth factor receptor inhibition strategies in pancreatic cancer: past, present and the future. JOP (2007) 0.89

Unilateral hand-foot syndrome: an extraordinary side effect of capecitabine. Cutan Ocul Toxicol (2010) 0.88

Docetaxel second-line therapy in patients with advanced pancreatic cancer: a retrospective study. Anticancer Res (2010) 0.88

First-line treatment of metastatic pancreatic adenocarcinoma: can we do better? Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010. JOP (2010) 0.88

Hypersensitivity reactions to docetaxel: retrospective evaluation and development of a desensitization protocol. Int Arch Allergy Immunol (2011) 0.87

Expectoration of a lung metastasis in a patient with colorectal carcinoma. Clin Colorectal Cancer (2008) 0.87

Medullary carcinoma of the colon: a case series and review of the literature. In Vivo (2014) 0.87

Early detection of pancreatic cancer. JOP (2012) 0.87

Staphylococcus aureus bacteremia related with erlotinib skin toxicity in a patient with pancreatic cancer. JOP (2009) 0.87

Updates of adjuvant therapy in pancreatic cancer: where are we and where are we going? Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010. JOP (2010) 0.86

Novel agents in the treatment of unresectable neuroendocrine tumors. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011. JOP (2011) 0.86

Quality of life in patients with pancreatic cancer. JOP (2012) 0.86

Update on novel therapies for pancreatic neuroendocrine tumors. JOP (2012) 0.86

Locally advanced pancreatic cancer. Looking beyond traditional chemotherapy and radiation. JOP (2013) 0.86

Modified docetaxel-cisplatin in combination with capecitabine as first-line treatment in metastatic gastric cancer. a phase II study. Anticancer Res (2012) 0.86

Gemcitabine-induced pulmonary toxicity. Anticancer Res (2012) 0.86

Locally advanced pancreatic adenocarcinoma: where are we and where are we going? Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011. JOP (2011) 0.86

Docetaxel versus docetaxel plus gemcitabine as front-line treatment of patients with advanced non-small cell lung cancer: a randomized, multicenter phase III trial. Lung Cancer (2007) 0.85

Pharmacogenomics and pancreatic cancer treatment. Optimizing current therapy and individualizing future therapy. JOP (2008) 0.85

Secondary tumors of the pancreas: a case series. Anticancer Res (2012) 0.85

Pancreatic adenocarcinoma with supraclavicular lymph node metastasis: is this the Virchow's node? JOP (2011) 0.85

Nutritional status of patients with locally advanced pancreatic cancer: a pilot study. Support Care Cancer (2010) 0.85

DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY (DPD) IN GI MALIGNANCIES: EXPERIENCE OF 4-YEARS. Pak J Med Sci (2007) 0.85

Pancreatic neuroendocrine tumors: entering a new era. JOP (2012) 0.85

Any progress in the management of advanced pancreatic cancer? Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009. JOP (2009) 0.85

Management of borderline resectable pancreatic adenocarcinoma. JOP (2012) 0.84

Biomarkers for early detection and screening in pancreatic cancer. Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009. JOP (2009) 0.84

Metastatic cervical carcinoma to the thyroid gland: a case report and review of the literature. Yale J Biol Med (2006) 0.84

Ampullary and periampullary tumors: translational efforts to meet a challenge in diagnosis and treatment. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011. JOP (2011) 0.84

Prognostic stratification of patients with advanced renal cell carcinoma treated with sunitinib: comparison with the Memorial Sloan-Kettering prognostic factors model. BMC Cancer (2010) 0.84

Cutaneous metastasis in a patient with pancreatic cancer. JOP (2011) 0.84

Targeted therapy for oesophageal cancer: an overview. Cancer Metastasis Rev (2008) 0.84

Novel agents for the treatment of pancreatic adenocarcinoma: any light at the end of the tunnel? Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010. JOP (2010) 0.84

Advancements in the management of pancreatic cancer. JOP (2009) 0.83

Intraductal papillary mucinous neoplasms of the pancreas (IPMNs): epidemiology, diagnosis and future aspects. JOP (2013) 0.83

Updates in locally advanced pancreatic cancer. Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010. JOP (2010) 0.83

Diabetes and pancreatic cancer. JOP (2014) 0.83

PARP-inhibitors in BRCA-associated pancreatic cancer. JOP (2014) 0.83

First-line treatment for advanced pancreatic cancer. JOP (2013) 0.83

Neuroendocrine tumors of the pancreas: what's new. Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010. JOP (2010) 0.83

Adjuvant therapy for pancreatic cancer. JOP (2014) 0.83

Pancreatic cancer: is this bleak landscape finally changing? Highlights from the '43rd ASCO Annual Meeting'. Chicago, IL, USA. June 1-5, 2007. JOP (2007) 0.82